Koss Olinger Consulting LLC Acquires 9,685 Shares of CRISPR Therapeutics AG $CRSP

Key Points

• Koss Olinger Consulting LLC increased its stake in CRISPR Therapeutics AG by 29.8%, acquiring an additional 9,685 shares and bringing its total holdings to 42,197 shares, valued at approximately $2,052,000.
• Insiders have sold 56,213 shares of CRISPR Therapeutics stock in the last three months, with General Counsel and CEO reporting significant decreases in their ownership percentages.
• Despite reporting a negative EPS of ($1.29) for the last quarter, CRISPR Therapeutics experienced a 72.5% year-over-year increase in revenue, highlighting potential growth amid challenges.

Koss Olinger Consulting LLC boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 29.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,197 shares of the company's stock after acquiring an additional 9,685 shares during the period. Koss Olinger Consulting LLC's holdings in CRISPR Therapeutics were worth $2,052,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CRSP. SVB Wealth LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at about $25,000. Costello Asset Management INC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at about $27,000. Quantbot Technologies LP boosted its holdings in shares of CRISPR Therapeutics by 272.4% in the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock valued at $45,000 after buying an additional 978 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of CRISPR Therapeutics by 24.6% in the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company's stock valued at $45,000 after buying an additional 181 shares in the last quarter. Finally, GF Fund Management CO. LTD. boosted its holdings in shares of CRISPR Therapeutics by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company's stock valued at $74,000 after buying an additional 394 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,076 shares of the firm's stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares of the company's stock, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 50,895 shares of the firm's stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares of the company's stock, valued at $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,213 shares of company stock valued at $3,810,458 over the last three months. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Up 0.6%

CRSP stock opened at $67.61 on Monday. The firm has a 50 day moving average of $61.62 and a 200 day moving average of $51.52. The stock has a market capitalization of $6.15 billion, a PE ratio of -12.45 and a beta of 1.84. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. The company had revenue of $0.89 million during the quarter, compared to analysts' expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics's revenue for the quarter was up 72.5% on a year-over-year basis. During the same period last year, the business earned ($1.49) EPS. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CRSP shares. JPMorgan Chase & Co. started coverage on shares of CRISPR Therapeutics in a report on Thursday, September 18th. They issued an "overweight" rating and a $70.00 price target on the stock. Royal Bank Of Canada raised their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a report on Tuesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Friday. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Finally, Barclays raised their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Ten investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and a consensus target price of $72.59.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.